American Institute of Advancement connects U.S. biomedical innovators with established international healthcare ecosystems—and gives international partners a structured path to emerging U.S. science, technologies, and clinical collaborations.
Connect with selected U.S.-developed technologies in regenerative medicine, cell- and tissue-based therapies, advanced molecular and biomarker diagnostics, and precision medicine—including clinically validated and FDA-cleared or approved technologies—and explore opportunities for clinical, institutional, licensing, and commercial collaboration.
Expand U.S.-developed regenerative medicine technologies, cell and tissue therapies, advanced diagnostics, precision medicine platforms, and other clinically relevant biomedical technologies into selected international markets.
American Institute of Advancement supports market assessment, regulatory and institutional navigation, partner identification, and commercialization pathways.
Promising biomedical technologies often benefit from early engagement with clinical, scientific, and institutional partners beyond their country of origin.
American Institute of Advancement brings together U.S. scientists, research institutions, technology developers, and international healthcare partners to explore opportunities in regenerative medicine, advanced diagnostics, and other translational biomedical fields.
We focus on the elements that matter to successful collaboration: scientific relevance, clinical need, regulatory considerations, technology readiness, and the appropriate institutional partners.
The goal is to create well-structured collaborations that support evaluation, clinical translation, and responsible introduction of new biomedical technologies into international healthcare settings.
Evaluate biological rationale, preclinical and clinical evidence, analytical/clinical validation, IP position, and technology readiness.
Assess regulatory status, manufacturing and quality requirements, clinical-use pathway, and market-specific adoption requirements.
Identify qualified hospitals, laboratories, research institutions, clinical investigators, distributors, and strategic partners relevant to the technology.
Support licensing, distribution, clinical validation, technology transfer, training, and implementation required for international deployment.
Cell therapies, tissue engineering, regenerative platforms, and related enabling technologies.
Molecular diagnostics, biomarker-based testing, imaging technologies, AI-assisted diagnostics, and screening platforms.
Technologies supporting patient stratification, targeted treatment selection, and individualized clinical decision-making.
Every biologic is supported by comprehensive documentation, standardized quality systems, and complete chain-of-custody records from laboratory processing through controlled global distribution.
Gain access to advanced biologic systems designed for use across regenerative, longevity, fertility, aesthetic, and recovery-focused clinical programs through physician and institutional networks.
These capabilities come together around the biomedical technologies we evaluate, advance, and connect with qualified clinical, institutional, and strategic partners.
The following areas represent the principal technology domains where American Institute of Advancement supports translation from scientific innovation toward clinical validation, implementation, and international deployment.
Advancing clinically relevant biomedical technologies across regenerative medicine, diagnostics, immunotherapy, and tissue engineering.
American Institute of Advancement works with scientifically credible technologies with defined translational potential, supporting their progression toward clinical validation, implementation, and international market access.
Cell-based and cell-derived approaches directed toward tissue repair, regeneration, and restoration of function.
Molecular, cellular, and biomarker-based technologies for disease detection, characterization, patient stratification, and therapeutic monitoring.
Cellular and biologic approaches designed to modulate immune responses for therapeutic application.
Engineered tissues, scaffolds, matrices, biomaterials, and combination approaches for tissue reconstruction and functional repair.
Gene replacement, gene editing, RNA-based therapeutics, and vector-mediated approaches for targeted modification of gene expression or function.
info@aiabiomed.com
Miami, FL, USA
American Institute of Advancement welcomes confidential discussions with researchers, technology owners, biomedical startups, research institutions, healthcare organizations, and strategic partners exploring scientifically credible technologies with clinical and international potential.
